The relationship between cancer and inflammation is well known since 1863 when Rudolf Virchow, following the observation of leukocytes in neoplastic tissues, hypothesized that chronic inflammation could contribute to the tumorigenic process. In the following decades, several lines of evidence suggested a strong association between chronic inflammation and increased susceptibility to neoplastic transformation and cancer development. It was estimated that up to 20% of all tumors arise from conditions of persistent inflammation such as chronic infections or autoimmune diseases. Indeed, the associations are well known between cervical cancer and papilloma virus, gastric cancer and Helicobacter pylori induced gastritis, esophageal adenocarcinoma and Barrett's metaplasia, hepatocellular carcinoma, hepatitis B and C viral infections, and many others. Some of the mechanisms forming the basis of the relationship between inflammation and tumor have been recently elucidated. The inflammatory microenvironment of neoplastic tissues is characterized by the presence of host leukocytes both in the supporting stroma and among the tumor cells, with macrophages, dendritic cells, mast cells, and T cells being differentially distributed (Balkwill and Mantovani, ). Several cytokines (TNF, IL-1, IL-6) and chemokines that are produced by the tumor cells and by leukocytes and platelets associated with the tumor have been found to be able to maintain the invasive phenotype (Coussens and Werb, ). Tumor-associated macrophages (TAMs) are a major component of the leukocyte infiltrate, initially recruited by inflammatory chemokines (e.g., CCL2) and then sustained by cytokines present in the tumor microenvironment (e.g., CSFs, VEGF-A). In response to cytokines such as TGF-β, IL-10, and M-CSF, TAMs promote tumor proliferation and progression and stroma deposition and, indeed, the density of TAMs is increased in advanced thyroid cancers (Ryder et al., 2008). As far as papillary thyroid cancer (PTC) is concerned, this tumor is frequently associated with autoimmune thyroid diseases, Graves’ disease, and Hashimoto's thyroiditis. The frequency of association is extremely variable in the series from different countries, 0–9% for Graves’ and 9–58% for Hashimoto's (Figure 1). It is still debated whether association with an autoimmune disorder could influence the prognosis of PTC. Indeed a worse prognosis was reported in few series (Ozaki et al., 1990; Pellegriti et al., 1998), while the majority of the studies showed either a protective effect of thyroid autoimmunity (Matsubasyashi et al., 1995; Loh et al., 1999; Gupta et al., ) or a similar behavior between cancer with and without associated thyroiditis (Yano et al., 2007). These discrepancies can be due to either the low number of patients examined in those studies, the lack of a control group, the existence of different genetic and epidemiological backgrounds, or the use of inappropriate criteria to define remission or persistence/relapse. We recently produced data extending the knowledge about the tight relationships among thyroiditis and thyroid cancer. In particular, the clinical and molecular features, and the expression of inflammation-related genes, were investigated in a large series of PTCs divided in two groups according to the association or not of the tumor with thyroiditis (Muzza et al., 2010). Interestingly, no significant differences between the two groups were found, as far as age at diagnosis, gender distribution, TNM staging, histological variants, and outcome are concerned, suggesting that the association with an autoimmune thyroid process does not modify either the presentation or the clinical behavior of PTC. A crucial finding of the last few years concerns the genetic background of PTCs, since the concept has emerged that the inflammatory protumourigenic microenvironment of this cancer is elicited by the oncogenes responsible for thyroid neoplastic transformation (such as RET/PTC, BRAFV600E, and RASG12V; Borrello et al., , ; Melillo et al., 2005; Mantovani et al., 2008). In particular, we recently demonstrated that the RET/PTC1 oncogene activates a transcriptional proinflammatory program in normal human primary thyrocytes (Borrello et al., ). Moreover, gene expression studies in cellular systems showed that not only RET/PTC but also RAS and BRAF proteins, all belonging to the RET–PTC/RAS/BRAF/ERK pathway, are able to induce the up-regulation of chemokines, which in turn could contribute to neoplastic proliferation, survival, and migration (Melillo et al., 2005). Consistently, other Authors demonstrated that RET/PTC3-thyrocytes express high levels of proinflammatory cytokines (Russel et al., 2003) and proteins involved in the immune response (Puxeddu et al., 2005). These data are well in agreement with our recent study which firstly showed that PTCs harbor a different genetic background according to the association or not with thyroiditis (Muzza et al., 2010). In particular, RET/PTC was more represented in patients with PTC and autoimmunity, while BRAFV600E was significantly more frequent in patients with PTC alone. Moreover, we showed that the expression of genes encoding three inflammation-related genes (CCL20, CXCL8, and l-selectin) was enhanced either in BRAFV600E or in RET/PTC tumors, compared with normal samples. Interestingly, non-neoplastic tissues with thyroiditis displayed the same levels of expression of CCL20 and CXCL8 compared to normal samples, suggesting that these inflammatory molecules could be associated with tumor-related inflammation, and not with the autoimmune process.
Figure 1
In conclusion, recent studies opened a new and extremely attractive scenario on the “connection” between thyroid autoimmunity, inflammation, and cancer. The interest is linked not only to the possibility of better understanding the communication between abnormally growing cells and their microenvironment, but also to the chance to pharmacologically interfere with such pro-tumor interactions.
References
1
BalkwillF.MantovaniA. (2001). Inflammation and cancer: back to Virchow?Lancet357, 539–545.10.1016/S0140-6736(00)04046-0
2
BarakateM. S.AgarwalG.ReeveT. S.BarracloughB.RobinsonB.DelbridgeL. W. (2002). Total thyroidectomy is now the preferred option for the surgical management of Graves’ disease. Aust. N. Z. J. Surg.72, 321–324.10.1046/j.1445-2197.2002.02400.x
3
BeharR.ArganiniM.WuT. C.McCormickM.StrausF. H.DeGrootL. J.KaplanE. L. (1986). Graves'disease and thyroid cancer. Surgery100, 1121–1127.
4
BelfioreA.GarofaloM. R.GiuffridaD.RunelloF.FilettiS.FiumaraA.IppolitoO.VigneriR. (1990). Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J. Clin. Endocrinol. Metab.70, 830–835.10.1210/jcem-70-4-830
5
BoostromS.RichardsM. L. (2007). Total thyroidectomy is the preferred treatment for patients with Graves’ disease and a thyroid nodule. Otolaryngol. Head Neck Surg.136, 278–281.10.1016/j.otohns.2006.09.011
6
BorrelloM. G.AlbertiL.IscherA.Degl'innocentiD.FerrarioC.GariboldiM.MarchesiF.AllavenaP.GrecoA.ColliniP.PilottiS.CassinelliG.BressanP.FugazzolaL.MantovaniA.PierottiM. A. (2005). Induction of proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U.S.A.102, 14825–14830.10.1073/pnas.0503039102
7
BorrelloM. G.Degl'InnocentiD.PierottiM. (2008). Inflammation and cancer: the oncogene-driven connection. Cancer Lett.267, 262–270.10.1016/j.canlet.2008.03.060
8
BradleyE. L.LiechtyR. D. (1983). Modified subtotal thyroidectomy for Graves’ disease: a two-institution study. Surgery94, 955.
9
CantalamessaL.BaldiniM.OrsattiA.MeroniL.AmodeiV.CastagnoneD. (1999). Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Arch. Intern. Med.159, 1705–1708.10.1001/archinte.159.15.1705
10
CappelliC.BragaM.De MartinoE.CastellanoM.GandossiE.AgostiB.CumettiD.PirolaI.MattanzaC.CherubiniL.Agabati RoseiE. (2006). Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: experience at an endocrine center in Italy. Surg. Today36, 125–130.10.1007/s00595-005-3115-3
11
CarnellN. E.ValenteW. A. (1998). Thyroid nodules in Graves’ disease: classification, characterization, and response to treatment. Thyroid8, 647–652.10.1089/thy.1998.8.571
12
ChouF. F.Sheen-ChenS. M.ChenY. S.ChenM. J. (1993). Hyperthyroidism and concurrent thyroid cancer. Int. Surg.78, 343–346.
13
CoussensL. M.WerbZ. (2002). Inflammation and cancer. Nature420, 860–867.10.1038/nature01322
14
DobynsB. M.ShelineG. E.WorkmanJ. B.TompkinsE. A.McConaheyW. M.BeckerD. V. (1974). Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J. Clin. Endocrinol. Metab.38, 976–998.10.1210/jcem-38-6-976
15
FarbotaL. M.CalandraD. B.LawrenceA. M.PaloyanE. (1985). Thyroid carcinoma in Graves’ disease. Surgery98, 1148–1153.
16
FioreE.RagoT.LatrofaF.ProvenzaleM. A.PiaggiP.DelitalaA.ScutariM.BasoloF.Di CoscioG.GrassoL.PincheraA.VittiP. (2011). Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr. Relat. Cancer18, 429–437.10.1530/ERC-11-0028
17
GabrieleR.LetiziaC.BorgheseM.De TomaG.CeliM.IzzoL.CavallaroA. (2003). Thyroid cancer in patients with hyperthyroidism. Horm. Res.60, 79–83.10.1159/000071875
18
GuptaS.PatelA.FolstadA.FentonC.DinauerC. A.TuttleR. M.ConranR.FrancisG. L. (2001). Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J. Clin. Endocrinol. Metab.86, 1346–1354.10.1210/jc.86.3.1346
19
HalesI. B.McElduffA.CrummerP.Clifton-BlighP.DelbridgeL.HoschlR.PooleA.ReeveT. S.WilmshurstE.WisemanJ. (1992). Does Graves’ disease or thyrotoxicosis affect the prognosis of thyroid cancer?J. Clin. Endocrinol. Metab.75, 886–889.10.1210/jc.75.3.886
20
HancockB. W.BingR. F.DirmikisS. M.MunroD. S.NealF. E. (1977). Thyroid carcinoma and concurrent hyperthyroidism – A study of ten patients. Cancer39, 298–302.10.1002/1097-0142(197701)39:1<298::AID-CNCR2820390146>3.0.CO;2-C
21
KasugaY.SugenoyaA.KobayashiS.KanekoG.MasudaH.FujimoriM.IidaF. (1990). Clinical evaluation of the response to surgical treatment of Graves’ disease. Surg. Gynecol. Obstet.170, 327.
22
KebebewE.TreselerP.ItuarteC. (2001). Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J. Surg.25, 632–637.10.1007/s002680020165
23
KimW. B.HanS. M.KimT. Y.Nam-GoongS.IIGongG.LeeH. K.HongS. J.ShongY. K. (2004). Ultrasonographic screening for detection of thyroid cancer in patients with Graves’ disease. Clin. Endocrinol.60, 719–725.10.1111/j.1365-2265.2004.02043.x
24
KraimpsJ. L.Bouin-PineauM. H.MaréchaudR.BarbierJ. (1998). Graves’ disease and thyroid nodules, a not exceptional association. Ann. Chir.52, 449–451.
25
KraimpsJ. L.Bouin-PineauM. H.MathonnetM.De CalanL.RoncerayJ.VissetJ.MarechaudR.BarbierJ. (2000). Multicentre study of thyroid nodules in patients with Graves’ disease. Br. J. Surg. 87, 764–775.10.1046/j.1365-2168.2000.01504.x
26
LarsonS.JacksonL.RiallT.UchidaT.ThomasR.QiuS.EversB. (2007). Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J. Am. Coll. Surg.204, 764–775.10.1016/j.jamcollsurg.2006.12.037
27
LinC. H.ChiangF. Y.WangL. F. (2003). Prevalence of thyroid cancer in hyperthyroidism treated by surgery. Kaohsiung J. Med. Sci.19, 379–384.10.1016/S1607-551X(09)70460-7
28
LinosD. A.KarakitsosD.PapademetriouJ. (1997). Should the primary treatment of hyperthyroidism be surgical?Eur. J. Surg.163, 651.
29
LohK. C.GreenspanF. S.DongF.MillerT. R.YeoP. P. B. (1999). Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.84, 458–462.10.1210/jc.84.2.458
30
MantovaniA.AllavenaP.SicaA.BalkwillF. (2008). Cancer-related inflammation. Nature54, 436–444.10.1038/nature07205
31
MatsubasyashiS.KawaiK.MatsumotoY.MukutaT.MoritaT.HiraiK.MatsukuzaF.KakudohK.KumaK.TamaiH. (1995). The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J. Clin. Endocrinol. Metab.80, 3421–3424.10.1210/jc.80.12.3421
32
MelilloR. M.CastelloneM. D.GuarinoV.De FalcoV.CiraficiA.SalvatoreG.CaiazzoF.BasoloF.GianniniR.KruhofferM.OrntoftT.FuscoA.SantoroM. (2005). The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest.115, 1068–1081.10.1172/JCI22758
33
MelliereD.EtienneG.BecqueminJ. P. (1988). Operation for hyperthyroidism: methods and rationale. Am. J. Surg.155, 395–399.10.1016/S0002-9610(88)80098-9
34
MiccoliP.VittiP.RagoT.IacconiP.BartalenaL.BogazziF.FioreE.ValerianoR.ChiovatoL.RocchiR.PincheraA. (1996). Surgical treatment of Graves’ disease: subtotal or total thyroidectomy?Surgery120, 1020–1024.10.1016/S0039-6060(96)80049-3
35
MssrouriR.BenamrS.EsadelA.MdaghriJ.Mohammadine elH.LahlouM. K.TaghyA.BelmahiA.ChadB. (2008). Thyroid cancer in patients with Graves’ disease. J. Chir. (Paris)145, 244–246.
36
MuzzaM.Degl'InnocentiD.ColomboC.PerrinoM.RavasiE.RossiS.CirelloV.Beck-PeccozP.BorrelloM. G.FugazzolaL. (2010). The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin. Endocrinol.72, 702–708.10.1111/j.1365-2265.2009.03699.x
37
OhmoriN.MiyakawaM.OhmoriK.TakanoK. (2007). Ultrasonographic findings of papillary thyroid carcinoma with Hashimoto's thyroiditis. Intern. Med.46, 547–550.10.2169/internalmedicine.46.1901
38
OzakiO.ItoK.KobayashiK.ToshimaK.IwasakiH.YashiroT. (1990). Thyroid carcinoma in Graves’ disease. World J. Surg.14, 437–440.10.1007/BF01658550
39
OzouxJ. P.de CalanL.PortierG.RivallainB.FavreJ. P.RobierA.GogaD.BrizonJ. (1988). Surgical treatment of Graves’ disease. Am. J. Surg.156, 177–181.10.1016/S0002-9610(88)80060-6
40
PaciniF.EliseiR.Di CoscioG. C.AnelliS.MacchiaE.ConcettiR.MiccoliP.ArganiniM.PincheraA. (1988). Thyroid carcinoma in thyrotoxic patients treated by surgery. J. Endocrinol. Invest.11, 107–112.
41
PellegritiG.BelfioreA.GiuffridaD.LupoL.VigneriR. (1998). Outcome of differentiated thyroid cancer in Graves’ patients. J. Clin. Endocrinol. Metab.83, 2805–2809.10.1210/jc.83.8.2805
42
PhitayakornR.McHenryC. R. (2008). Incidental thyroid carcinoma in patients with Graves’ disease. Am. J. Surg.195, 292–297.10.1016/j.amjsurg.2007.12.006
43
Pino RiveroV.Guerra CamachoM.Marcos GarcĂaM.Trinidad RuizG.Pardo RomeroG.González PalominoA.Blasco HuelvaA. (2004). The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Our experience and literature review. An Otorrinolaringol. Ibero Am.31, 223–230.
44
PomorskiL.CywińskiJ.RybińskiK. (1996). Cancer in hyperthyroidism. Neoplasma43, 217–219.
45
PuxedduE.KnaufJ. A.SartorM. A.CastelloneM. D.SantoroM.RothsteinJ. L. (2005). RET/PTC induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr. Relat. Cancer12, 319–334.10.1677/erc.1.00947
46
RazackM. S.LoreJ. M.LippesH. A.SchaeferD. P.RassaelH. (1997). Total thyroidectomy for Graves’ disease. Head Neck19, 378–383.10.1002/(SICI)1097-0347(199708)19:5<378::AID-HED3>3.3.CO;2-N
47
RiegerR.PimplW.MoneyS.RettenbacherL.GalvanG. (1989). Hyperthyroidism and concurrent thyroid malignancies. Surgery106, 6–10.
48
RusselJ. P.ShinoaraS.MelilloR. M.CastelloneM. D.SantoroM.RothsteinJ. L. (2003). Tyrosine kinase oncoprotein, RET/PTC3, indices the secretion of myeloid growth and chemotactic factors. Oncogene22, 4569–4577.10.1038/sj.onc.1206759
49
RyderM.GhosseinR. A.Ricarte-FilhoJ. C.KnaufJ. A.FaginJ. A. (2008). Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer15, 1069–1074.10.1677/ERC-08-0036
50
ShapiroS. J.FriedmanN. B.PerzikS. L.CatzB. (1970). Incidence of thyroid carcinoma in Graves’ disease. Cancer26, 1261–1270.10.1002/1097-0142(197012)26:6<1261::AID-CNCR2820260613>3.0.CO;2-P
51
TamimiD. M. (2002). The association between chronic lymphocytic thyroiditis and thyroid tumors. Int. J. Surg. Pathol.10, 14–16.10.1177/106689690201000207
52
TerzioğluT.TezelmanS.OnaranY.TanakolR. (1993). Concurrent hyperthyroidism and thyroid carcinoma. Br. J. Surg.80, 1301–1302.10.1002/bjs.1800801027
53
WahlR. A.GoretzkiP.MeybierH.NitschkeJ.LinderM.RöherH. D. (1982). Coexistence of hyperthyroidism and thyroid cancer. World J. Surg.6, 385–390.10.1007/BF01657662
54
WeberK. J.SolorzanoC. C.LeeJ. K.GaffudM. J.PrinzR. A. (2006). Thyroidectomy remains an effective treatment option for Graves’ disease. Am. J. Surg.191, 400–405.10.1016/j.amjsurg.2005.10.043
55
YanoY.ShibuyaH.KitagawaW.NagahamaM.SuginoK.ItoK.ItoK. (2007). Recent outcome of Graves’ disease patients with papillary thyroid cancer. Eur. J. Endocrinol.157, 325–329.10.1530/EJE-07-0136
56
ZanellaE.RulliF.SianesiM.SciacchitanoS.DaneseD.PontecorviA.FarinonA. M. (2001). Hyperthyroidism with concurrent thyroid cancer. Ann. Ital. Chir.72, 293–297.
57
ZivaljevićV. R.DiklićA. D.KrovićK. L.ZorićG. V.ZivićR. V.KalezićN. K.KazićM. T.TatićS. B.HavelkaM. J.PaunovićI. R. (2008). The incidence rate of thyroid microcarcinoma during surgery benign disease. Acta Chir. Iuglos.55, 69–73.10.2298/ACI0804069V
Summary
Keywords
Autoimmunity, Chemokines, Cytokines, Inflammation, papilalry thyroid cancer, RET, thyroid, Thyroiditis
Citation
Fugazzola L, Colombo C, Perrino M and Muzza M (2011) Papillary Thyroid Carcinoma and Inflammation. Front. Endocrin. 2:88. doi: 10.3389/fendo.2011.00088
Received
08 September 2011
Accepted
14 November 2011
Published
16 December 2011
Volume
2 - 2011
Copyright
© 2011 Fugazzola, Colombo, Perrino and Muzza.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
*Correspondence: laura.fugazzola@policlinico.mi.it
This article was submitted to Frontiers in Cancer Endocrinology, a specialty of Frontiers in Endocrinology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.